CoChat
Sign Up
Cited by 2,159Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

Open access
Brown, Greg, Albers, John J., Fisher, Lloyd D., Schaefer, Susan M., Lin, Jiin-Tarng, Kaplan, Cheryl, Zhao, Xue-Qiao, Bisson, Brad D., Fitzpatrick, Virginia F., Dodge, Harold T.·1990·New England Journal of Medicine
DOI 10.1056/nejm199011083231901
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND AND METHODS: The effect of intensive lipid-lowering therapy on coronary atherosclerosis among men at high risk for cardiovascular events was assessed by quantitative arteriography. Of 146 men no more than 62 years of age who had apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary artery disease, and a family history of vascular disease, 120 completed the 2 1/2-year double-blind study, which included arteriography at base line and after treatment. Patients were given dietary counseling and were randomly assigned to one of three treatments: lovastatin (20 mg twice a day) and colestipol (10 g three times a day); niacin (1 g four times a day) and colestipol (10 g three times a day); or conventional therapy with placebo (or colestipol if the low-density lipoprotein [LDL] cholesterol level was elevated). RESULTS: The levels of LDL and high-density lipoprotein (HDL) cholesterol changed only slightly in the conventional-therapy group (mean changes, -7 and +5 percent, respectively), but more substantially among patients treated with lovastatin and colestipol (-46 and +15 percent) or niacin and colestipol (-32 and +43 percent). In the conventional-therapy group, 46 percent of the patients had definite lesion progression (and no regression) in at least one of nine proximal coronary segments; regression was the only change in 11 percent. By comparison, progression (as the only change) was less frequent among patients who received lovastatin and colestipol (21 percent) and those who received niacin and colestipol (25 percent), and regression was more frequent (lovastatin and colestipol, 32 percent; niacin and colestipol, 39 percent; P less than 0.005). Multivariate analysis indicated that a reduction in the level of apolipoprotein B (or LDL cholesterol) and in systolic blood pressure, and an increase in HDL cholesterol correlated independently with regression of coronary lesions. Clinical events (death, myocardial infarction, or revascularization for worsening symptoms) occurred in 10 of 52 patients assigned to conventional therapy, as compared with 3 of 46 assigned to receive lovastatin and colestipol and 2 of 48 assigned to receive niacin and colestipol (relative risk of an event during intensive treatment, 0.27; 95 percent confidence interval, 0.10 to 0.77). CONCLUSIONS: In men with coronary artery disease who were at high risk for cardiovascular events, intensive lipid-lowering therapy reduced the frequency of progression of coronary lesions, increased the frequency of regression, and reduced the incidence of cardiovascular events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199011083231901

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. 10.1001/jama.251.3.351 · DOI · Paper page
  2. Brown, 1989, Arteriosclerosis, 9, 1–81
  3. Bruce, 1971, Ann Clin Res, 3, 323
  4. SAS Institute Inc. SAS user's guide: statistics; version 5 edition. Cary, N.C.: SAS Institute, 1985:607–14.
  5. Rosner B. Fundamentals of biostatistics. 2nd ed. Boston: Duxbury Press, 1986:326–32.
  6. Wagner, 1980, Am J Pathol, 100, 633

Cited by

Sorted by citations

See all 2,159

Related

See all

Metadata

Authors
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T.
Affiliations
University of Washington (US)
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
1990-11-08
Volume
323
Issue
19
Pages
1289-1298
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejm199011083231901
OpenAlex
W2324712847
Cited by
2,159
References
53
Citations by year
2026: 2 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 8 · 2021: 3 · 2020: 10 · 2019: 14 · 2018: 13 · 2017: 17 · 2016: 28 · 2015: 29 · 2014: 29 · 2013: 38 · 2012: 48
FWCI
202.83
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hl019451-14)
  • National Heart, Lung, and Blood Institute (P01HL030086, R01 HL 19451)
  • National Center for Research Resources (RR 37)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
coronary artery disease, apolipoprotein B, intensive lipid-lowering therapy, lovastatin, nicotinic acid, colestipol, LDL cholesterol, HDL cholesterol, systolic blood pressure, cardiovascular events, revascularization, myocardial infarction, mortality, nutrition counseling
MeSH terms
Adult, Apolipoproteins B, Colestipol, Coronary Disease, Diet, Double-Blind Method, Drug Therapy, Combination, Humans, Cholesterol, HDL, Cholesterol, LDL, Lovastatin, Male, Middle Aged, Niacin, Multivariate Analysis, Coronary Angiography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review